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ABSTRACT: The emergence of complex protein therapeu-
tics in general and monoclonal antibodies (mAbs) in
particular have stimulated analytical chemists to develop
new methods and strategies for their structural character-
ization. Mass spectrometry plays a key role in providing
information on the primary amino acid sequence, post-
translational modiﬁcations, and other structure characteristics
that must be monitored during the manufacturing process and
subsequent quality control assessment. In this study, we
present a novel method that allows structural characterization
of mAbs based on MALDI in-source decay (ISD)
fragmentation, coupled with Fourier transform ion cyclotron
resonance (FT-ICR) MS. The method beneﬁts from higher
resolution of absorption mode FT mass spectra, compared to magnitude mode, which enables simultaneous identiﬁcation of
ISD fragments from both the heavy and light chains with a higher conﬁdence in a wide mass range up to m/z 13 500. This
method was applied to two standard mAbs, namely NIST mAb and trastuzumab, in preparation for method application in an
interlaboratory study on mAbs structural analysis coordinated by the Consortium for Top-Down Proteomics. Extensive
sequence coverage was obtained from the middle-down analysis (IdeS- and GingisKHAN-digested mAbs) that complemented
the top-down analysis of intact mAbs. In addition, MALDI FT-ICR MS of IdeS-digested mAbs allowed isotopic-level proﬁling
of proteoforms with regard to heavy chain N-glycosylation.
Structural characterization of protein therapeutics is anessential part of their development and production
process.1−4 Regulatory authorities require in-depth character-
ization, and detailed quality control, of biopharmaceuticals to
demonstrate similarity of the drug substance from diﬀerent
batches, throughout the production process. Moreover,
structural analysis provides rationale for optimizing biophar-
maceuticals downstream processing and formulation studies.
The most important class of clinically approved protein
therapeutics are monoclonal antibodies (mAbs) of the
immunoglobulin G (IgG) class.5,6 The IgG molecule has a
symmetric Y-shaped structure that is composed of two
identical heavy chains (Hc, approximately 50 kDa each) and
two identical light chains (Lc, approximately 25 kDa each).
The Hc is typically N-glycosylated at one speciﬁc asparagine in
the fragment crystallizable (Fc) region.
Structural complexity in IgGs is increased by additional post-
translational modiﬁcations (PTMs) such as intra- and
interchain cysteine−cysteine connections (disulﬁde bonds),
possible polypeptide truncation, and chemical modiﬁcations
such as asparagine deamidation and methionine oxidation.
Consequently, comprehensive structural analysis of mAbs at a
proteoform level is a challenging task.7 Speciﬁcally, the read-
out of the primary sequence,8−10 mapping of disulﬁde
bonds,11,12 and proﬁling of protein glycosylation13−16 require
various strategies that add up to a time-consuming procedure.
These structural characteristics are monitored during the
manufacturing process and must meet the criteria deﬁned for
the critical quality attributes of each mAb.17
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Current MS-based characterization assays of mAbs utilize
primarily standard bottom-up proteomics strategies.18 Sample
preparation in these assays involves a reduction/alkylation
step, with an inherent risk of introducing artifacts, for example
when quantifying or localizing deamidation or oxidation.1
Furthermore, it is well-known that a bottom-up workﬂow can
miss detection of partial backbone cleavages or unexpected
modiﬁcations.19 Middle- and top-down strategies, in which the
mAb is only partially digested or left intact, can largely
overcome these issues.7 Such approaches are mostly carried
out on high-resolution electrospray ionization instruments.20,21
However, matrix-assisted laser desorption/ionization
(MALDI) in-source decay (ISD) MS is a powerful alternative
for primary structure characterizations of both N- and C-
terminal parts of proteins, including mAbs.22,23 In the MALDI-
ISD workﬂows, oﬀ-line reduction of disulﬁde bonds is avoided,
and reduction is instead achieved by using 1,5-diaminonaph-
thalene (1,5-DAN) as a MALDI matrix.24,25 The hydrogen-
donor property of this matrix results in the reduction of the
disulﬁde bonds during the ionization process.
In MALDI-ISD spectra, c-type fragment ions are usually the
most intense series, while z + 1- (or z + 2), w-, y-, b-, and a-
type fragments are less abundant. Most if not all fragment ions
obtained from MALDI-ISD are singly charged (protonated)
resulting in relatively simple mass spectra. Nonetheless, in case
a mixture of proteins or polypeptide subunits is considered,
such as for the analysis of an intact mAb (Hc and Lc) or its
middle-down products, the complexity of MALDI-ISD spectra
increases. Thus, mass measurements at ultrahigh resolution are
crucial for unambiguous identiﬁcation of ISD fragment ions in
a wide m/z-range. The most frequently used instruments in
MALDI-ISD MS are time-of-ﬂight (TOF) mass analyzers that
exhibit a limited resolving power.10 In a previous study, we
have shown that small (singly charged) proteins can be
measured at isotopic resolution up to about m/z 17 000 using
a 15T MALDI Fourier transform ion cyclotron resonance (FT-
ICR) MS system and that in-depth structural information on
these proteins can be obtained from ultrahigh resolution
MALDI-ISD spectra (with a resolving power of 62 000 at m/z
16 950).26 The sequence information obtained using this
method was complementary to the information obtained from
other fragmentation techniques. Notably, these previous
measurements were performed using mass spectra represented
in magnitude mode FT (mFT). The quality of FT-ICR MS
data can be further improved if absorption mode FT (aFT)
representation is used instead.27−30
In this study, we improved MALDI FT-ICR MS acquisition
methods and complemented these with the absorption-mode
FT mass spectral representation.31 This was applied to analyze
intact, and IdeS- and GingisKHAN-digested mAbs (NIST
mAb and trastuzumab), without the need of buﬀer exchange,
prior disulﬁde bond reduction, or chromatographic separation,
allowing the analysis of these mAbs by MS within few minutes.
The use of ultrahigh resolution MS allowed us to identify ISD
fragments in a wide m/z-range, leading to the extensive and
reliable structure characterization of mAbs.
■ EXPERIMENTAL SECTION
Chemicals. Two diﬀerent mAbs, namely trastuzumab
(HzIgG1kappa, CHO) and NIST mAb standard (HzIgG1-
kappa, NS0), were provided by the CTDP.32 Both mAbs were
provided in the intact form and in a digested (but not disulﬁde
bond reduced) form, using structure-speciﬁc enzymes IdeS or
GingisKHAN (Genovis, Lund, Sweden).33,34 Brieﬂy, intact
trastuzumab and NIST mAb standard were diluted from initial
concentrations of 21 and 10 mg/mL, respectively, to a ﬁnal
concentration of 2 mg/mL, using MQ water, and stored at −80
°C in 20-μL aliquots (in 500-μL Lobind Eppendorf tubes)
until further use.
Antibody subunits were generated in the following manner.
To induce mAb cleavage below the hinge region, intact mAbs
at 1 mg/mL in PBS, pH 6.8, were digested with 1000 units of
Fabricator (IdeS), according to the manufacturer’s instruc-
tions, at 37 °C for 30 min, under shaking (350 rpm). The
reaction was quenched by adding triﬂuoroacetic acid to a ﬁnal
concentration of ∼0.05% and the samples were stored at −80
°C until further use. To initiate mAb cleavage above the hinge
region, intact mAbs at 1 mg/mL in 100 mM Tris, pH 8, were
digested with 1000 units of GingisKHAN (Gingipain K),
according to the manufacturer’s instructions, at room temper-
ature (RT) for 1 h. The reaction was quenched by adding
triﬂuoroacetic acid to a ﬁnal concentration of ∼0.05%, and the
samples were stored at −80 °C until further use. All samples
were aliquoted and shipped on dry ice. 1,5-Diaminonaph-
thalene (1,5-DAN; handle with care, check material safety data
sheet), α-cyano-4-hydroxycinnamic acid (HCCA), horse
myoglobin, and acetonitrile (MS grade) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). A stock solution
of myoglobin at 2 mg/mL was prepared in water.
MALDI-Spotting. For ISD MS analysis, each sample (i.e.,
myoglobin, intact and digested mAbs) was diluted 1- to 10-fold
with MQ water and spotted onto a MALDI ground steel target
plate (Bruker Daltonics, Bremen, Germany) as follows. First, 1
μL of diluted sample was put on the plate, followed by addition
of 1 μL of 1,5-DAN (saturated solution in acetonitrile/water/
formic acid, 50%:49.95%:0.05%) using a 10-μL pipet tip
(Rainin tips from Mettler-Toledo, Tiel, Netherlands). Gentle
mixing of the 2-μL droplet was performed until small crystals
were visible by eye; then the mixture was allowed to dry at RT.
In addition, 1 μL of diluted IdeS digest was spotted with 1 μL
of α-cyano matrix (saturated solution in acetonitrile/water/
formic acid, 50%:49.95%:0.05%) in a similar way. A 200 μg/
mL solution of myoglobin (1 μL) was spotted with 1 μL of 1,5-
DAN (saturated solution in acetonitrile/water/formic acid,
50%:49.95%:0.05%) and used for external calibration of the
FT-ICR MS system.
MALDI Mass Spectrometry. All MALDI- and MALDI-
ISD FT-ICR MS experiments were performed as previously
reported, with some modiﬁcation of the acquisition methods.26
Brieﬂy, all MS experiments were performed on a Bruker 15 T
solariX XR FT-ICR mass spectrometer equipped with a
CombiSource and a ParaCell (Bruker Daltonics, Bremen,
Germany). The FT-ICR MS system was controlled by
ftmsControl software and equipped with a Smartbeam-II
Laser System (Bruker Daltonics) that operated at a frequency
of 500 Hz, and each single spectrum was generated from 200
laser shots. Higher trapping potentials (up to 9.5 V) and
ParaCell DC biases (up to 9.3 V) were used to improve the
mass measurement precision. Three mass spectra were
obtained from a single spot, using three acquisition methods
for the corresponding m/z-ranges: 1012−5000; 1012−7000
and 2024−30 000. A fourth acquisition method was used in
the m/z-range 3495−30 000 for glycoform analysis. For this
purpose, a second MALDI-spot was used. The measurement
time ranged from 0.98 min for the acquisitions in the m/z-
range 1012−5000 to 2.89 min for the acquisitions in the m/z-
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range 3495−30 000. A detailed description of the FT-ICR MS
parameters of the four applied acquisition methods is provided
in Supporting Information Table S1. The instrument was
externally calibrated using ISD fragments obtained from
myoglobin for the four diﬀerent acquisition methods.
Absorption Mode FT Spectra Representation. To
display an FTMS spectrum in the aFT, it is necessary to
correct for systematic phase shifts across the frequency range
that result from the methods used to induce coherent ion
motion in the respective instruments. Various methods have
been presented for solving this phase correction problem on
the Orbitrap20,30 and on FT-ICRs.28,29,31,35 In this study, the
FT-ICR MS data ﬁles were recorded to include the transient
data (ﬁd) ﬁle. The aFT mass spectra were generated directly
from the transient data ﬁles using AutoVectis software suite
(Spectroswiss, Lausanne, Switzerland) that incorporates an
improved version of the AutoPhaser method31 using a genetic
algorithm35 to optimize the phase correction function,36
applies an asymmetric apodization function to minimize
baseline deviations in the resulting absorption mode
spectrum,37 and generates synthetic isotopic distributions
with aFT peak proﬁles to aid peak identiﬁcation.38 The data
were processed by applying a full-bell, but asymmetric
apodization function (F = 0.4) to minimize baseline deviations
in the resulting aFT spectrum, while allowing balance between
the spectral resolution and signal-to-noise ratio across the
spectrum.37 After apodization, the transients were doubly zero-
padded before being processed using the default AutoVectis
settings. An internal calibration was applied before analysis in
Autoseequer tool. Fragment ions were assigned with an error
tolerance of 10, 20, and 40 ppm for the spectra acquired with
methods 1, 2, and 3, respectively (see Table S1). The tolerance
for the quality value for the match between the observed and
theoretical isotopic distribution was 0.65 for c- and z + 1-type
fragment and 0.60 for a-, b-, y-, and w-type. An internal
calibration of the spectra was also applied before spectral
interpretation using mMass.39 The theoretical c-type fragments
from the Lc of each mAb were used as internal calibrants of the
spectra generated from intact mAbs while the c-type fragments
from Fd subunit were used for the internal calibration of the
spectra generated from IdeS- and GingisKHAN-digested
mAbs.
Theoretical Isotopic Distributions for Figures. The
elemental composition of ISD fragments was calculated using
an in-house developed tool in Excel, and theoretical isotopic
abundance distributions were generated using the online tool
enviPat Web 2.2 (http://www.envipat.eawag.ch/index.php),40
exported in the “comma-separated value” format and compiled
in a text ﬁle. Plots were generated in Excel and exported in
Adobe Illustrator CS6 to make the ﬁgures.
N-Glycosylation at the Fc-Part. N-glycosylation of the
Fc-part of both NIST mAb and trastuzumab was evaluated.
The IdeS-based enzymatic cleavage of NIST mAb and
trastuzumab results in two identical Fc/2 parts (approximately
25 kDa each) and one F(ab)2 portion (approximately 100
kDa). We analyzed IdeS digests of both NIST mAb and
trastuzumab by MALDI FT-ICR MS using HCCA as MALDI
matrix without the use of any additional separation.
■ RESULTS AND DISCUSSION
MALDI-ISD FT-ICR MS of Intact and Digested NIST
mAb. Intact and both IdeS- and GingisKHAN-digested mAbs
were analyzed by MALDI-ISD FT-ICR MS. Ultrahigh
resolution MS analysis (estimated resolving power 660 000 at
m/z 400) was performed using three diﬀerent acquisition
methods to maximize both sensitivity and mass measurement
precision in the m/z range from 1012 to 13 500 (Figure 1).
Thus, obtained spectra from the analysis of intact NIST mAb
are combined in Figure 1A. Note that ISD fragments from
both light chain (Lc) and heavy chain (Hc) are detected
simultaneously. The combined spectra obtained from the
analysis of IdeS- and GingisKHAN-digested NIST mAb are
depicted in Figures 1B and C. IdeS is an enzyme that cleaves
the Hc of the NIST mAb below the hinge region, between
G239 and G240, whereas GingisKHAN cleaves above the
hinge region, between K225 and T226.33,34 The application of
Figure 1. MALDI-ISD FT-ICR MS analysis of (A) intact, (B) GingisKHAN-digested, and (C) IdeS-digested NIST mAb.
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1,5 DAN reduces the disulﬁde bonds during the MALDI
process. Thus, ISD fragment ions were simultaneously
generated from intact Lc, Fd, and Fc/2 digestion products.
The increased complexity of the IdeS/GingisKHAN-digested
mAb samples hampers unambiguous fragment ion assignments
especially at higher m/z-values (both in magnitude and
absorption mode). Consequently, fragment ions from digested
NIST mAb were assigned up to m/z 7000, whereas fragment
ions from intact NIST mAb were assigned up to m/z 13 500.
Magnitude-Mode FT versus Absorption-Mode FT
Mass Spectra. Resolving power is a key parameter in MS-
based analysis of complex samples. Overlapping peaks can
result in ambiguous identiﬁcations when mass resolution is not
suﬃcient. FT-ICR MS provides the highest resolving power
within the diﬀerent classes of mass spectrometers and allows
for the analysis of extremely complex samples such as
petroleum,41 mixtures of biomolecules,42 and nanomaterials.43
However, ultrahigh mass resolution (UHMR) requires
longer measurement time (seconds) with inherently reduced
sensitivity. Therefore, the measurement time was balanced
with ion intensities resulting in a maximum resolving power of
660 000 (magnitude mode FT, estimated at m/z 400, see
Table S1) for MALDI-ISD FT-ICR MS measurements. To
further improve resolving power the acquired ICR transients
were processed to obtain aFT mass spectra. To this end, we
used AutoVectis software to perform a phase correction of ICR
time-domain data with reduced baseline deviations. The results
of such a correction, in terms of improved resolving power and
increased identiﬁcation conﬁdence, are exempliﬁed in Figure 2.
Here, magnitude-mode visualization did not allow the
resolution of the isotopic distributions of the fragments c49 of
the Lc and of the fragment c51 and z + 148 of the Hc with pyro-
glutamate at the N-terminus and a lysine loss at the C-terminus
(Figure 2A). The postacquisition phase correction increased
the resolving power and thus resolved the three isotopic
distributions (Figure 2B). Note that the observed and
theoretical isotopic distribution of the z + 149 of the Lc did
not match, thus this fragment was not identiﬁed and not
included in the sequence coverage (Figure 3). Similarly, the
isotopic distribution of the fragment c47 of the Fc/2 fragment
and Lc and the fragments c48 and z + 144 of the Hc with
pyroglutamate at the N-terminus and a lysine loss at the C-
terminus that were not resolved in the mFT mass spectrum
(Figure 2D) could be distinguished after phase correction in
the aFT mass spectrum (Figure 2E).
Figure 2. Expanded views of MALDI-ISD FT-ICR mass spectra of NIST mAb showing the increased resolving power obtained after phase
correction of mFT mass spectra.
Figure 3. Sequence coverage obtained from the top-down and middle-down analysis of NIST mAb. Total sequence coverage was 50% and 65% for
Hc and Lc, respectively. Next to glycosylation, two additional proteoforms of the Hc were identiﬁed, namely a pyro-glutamine modiﬁcation at the
N-terminus and a lysine loss at the C-terminus.
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Identiﬁcation of ISD Fragment Ions. The identiﬁcation
of ISD fragment ions was performed using AutoVectis. In
addition, ISD spectra were visually inspected and matched to
theoretical isotopic distributions of fragment ions (Figure S1).
As described in the Experimental Section, we used three
diﬀerent acquisition methods to obtain optimal sensitivity in
diﬀerent m/z ranges. The sequence coverages for intact and
IdeS-digested NIST mAb were obtained using these methods
and AutoVectis (Figures S2 and S3). As an example, the mass
measurement errors of all c- and z + 1-type fragment ions
identiﬁed in the MALDI-ISD FT-ICR MS spectrum of IdeS-
digested NIST in the m/z-range 1000−7000 are reported in
Figure S4.
Most of the fragment ions were identiﬁed in both mFT and
aFT spectra and only a minor part were identiﬁed exclusively
in aFT spectra (data not shown). Phase correction led to
additional identiﬁcations only when isotopic distributions were
not resolved in mFT, for example, in the cases depicted in
Figure 2.
MALDI-ISD analysis of the same mAb samples has also
been performed using TOF MS. It is noted, however, that
TOF MS instruments exhibit a lower resolving power, with
corresponding limitations, even when Lc and Hc are analyzed
separately. Overlapping isotopic distributions can result from
fragment ions of diﬀerent forms of the same chain. For
example, the heavy chain c52 fragment ion with N-terminal
pyroglutamate and the z + 149 fragment ion from the Hc with a
C-terminal lysine-loss have monoisotopic peaks located at m/z
5528.871 and 5529.664, respectively (Figure S5). These
fragment ions are baseline-resolved by FT-ICR MS but not
by TOF MS.10 In addition to c-type ions, the most intense
fragment in the spectra, and z + 1-type ions, other fragment
types were detected and identiﬁed. Examples of y-, b-, a-, and
w-type fragments are depicted in Figure S6. In addition, we
identiﬁed these fragment types in the MALDI-ISD FT-ICR
MS spectrum generated from the analysis of IdeS-digested
NIST mAb in the m/z-range 1000−7000 (Figure S7).
Considering the total number of fragment ions identiﬁed in
this spectrum (see Figures S3 and S7), the percentage of c-, z +
1-, w-, a-, y-, and b-type were 42%, 22%, 12%, 11%, 11%, and
2%, respectively.
The identiﬁcation of diﬀerent fragment ion types improves
the conﬁdence in the structural characterization of mAbs. In
fact, less frequent fragment ions can be used either to
corroborate the identiﬁcations based on c- and z + 1-type ions
or to identify amino acids adjacent to prolines. A drawback of
additional fragment types is that the signal intensity is
distributed over many more fragment ions with a consequent
reduction of the signal-to-noise (S/N). In addition, the
presence of many fragment types complicates the ISD spectra,
making their interpretation more diﬃcult. At last, with a higher
number of fragment ions the false discovery rate (FDR) must
be evaluated when identiﬁcations are not manually conﬁrmed.
Sequence Coverage of NIST mAb. In this study, we have
developed a fast characterization method based on ultrahigh
resolution MALDI-ISD FT-ICR MS for the analysis of mAbs.
This method allowed the direct analysis of mAbs without the
need of a buﬀer exchange or a chromatographic separation of
Lc and Hc or Fd′ and Fc/2 digestion products. Using this
method, two modiﬁcations on Hc of the NIST mAb were
identiﬁed beyond glycosylation proﬁling, namely a pyrogluta-
mate at the N-terminus and a lysine-loss at the C-terminus.
The frequency of these two modiﬁcations was estimated at
100% and 50%, respectively. The analysis of intact NIST mAb
resulted in a sequence coverage of 31% and 65% for Hc and
Lc, respectively (Figure 3). The analysis of both IdeS and
GingisKHAN digests increased the sequence coverage for the
Hc up to 50%. The total sequence coverage for the
complementarity-determining regions (CDRs) was 72% and
96% for Hc and Lc, respectively.
Sequence Coverage of Trastuzumab mAb. MALDI-
ISD FT-ICR MS was also used to analyze trastuzumab. As for
the NIST mAb, the high resolving power allowed the reliable
identiﬁcation of diﬀerent types of ISD fragments in a wide
mass range. The sequence coverage obtained from the
identiﬁcation of c- and z + 1-type fragment ions is reported
in Figure S8. The analysis of the intact trastuzumab led to
sequence coverages of 29% and 56% for Hc and Lc,
respectively, while the analysis of both IdeS and GingisKHAN
digests allowed to increase the sequence coverage for Hc to
49%. The total sequence coverage for the CDRs was 93% and
80% for Hc and Lc, respectively. In a recent report,
trastuzumab was analyzed by ETD and HCD fragmentation.44
Our MALDI FT-ICR MS analysis of trastuzumab provided
sequence information that was complementary to the
information obtained. Also compared to similar IgG mAbs
using other fragmentation techniques MALDI-ISD FT-ICR
MS data is complementary.9,45−47 This is exempliﬁed for
adalimumab (middle-down LC-MS/MS using electron-transfer
dissociation) in Figure 4.9
In general, the sequence coverage obtained using mFT or
aFT data were similar. In fact, the number of fragment ions
identiﬁed in mFT spectra ranged from 95% to 100% the
number of fragment ions in the corresponding aFT spectra.
Figure 4. Sequence coverage of light chain obtained from the top-down MALDI-ISD FT-ICR MS analysis of trastuzumab compared to previously
reported middle-down analysis by LC-MS/MS with electron-transfer dissociation of adalimumab. The two methods resulted in complementary
sequence information as exempliﬁed in the areas highlighted in green. The diﬀerences in amino acid sequence between trastuzumab and
adalimumab are reported in red.
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This is rationalized by the fact that the resolving power in mFT
was already suﬃcient to identify most of the fragment ions.
Only a minor part of all identiﬁed fragment ions were
identiﬁed solely in aFT spectra. However, the identiﬁcation in
aFT is more reliable since a higher resolution allows detection
of possible overlapping species.
Glycosylation Analysis. The MALDI FT-ICR MS
strategies we report here also provide insight into N-
glycosylation of the Fc-part of both NIST mAb and
trastuzumab. Previously, in-depth glycosylation analysis
resulted in the identiﬁcation of tens of diﬀerent glycan
structures on the Hc of the IgG1 mAb.48 Most of these
proteoforms (glycoforms) were detected as minor compo-
nents, whereas a few diantennary glycans represented more
than 90% of the total glycosylation.49 The analysis of these
major proteoforms has been reported using lower resolution
MS in combination with up-front separation.49,50 The high-
resolution mFT spectra of IdeS-digested NIST mAb and
trastuzumab are depicted in Figure 5. The most abundant
glycoforms of Fc-parts of both NIST mAb and trastuzumab are
observed as doubly charged ions and, for the ﬁrst time,
identiﬁed at isotopic resolution. The relative abundance of
these glycoforms is in good agreement with previously
reported characterization studies of these mAbs.49,50
■ CONCLUSIONS
We have developed a novel strategy based on ultrahigh
resolution MALDI-ISD FT-ICR MS to characterize mAbs.
This strategy was applied to primary structure and proteoform
analysis of two IgG1 mAbs, namely NIST mAb standard and
trastuzumab. Complex top- and middle-down MALDI-ISD
FT-ICR mass spectra were generated from both intact mAbs
and their large, 25−50 kDa, subunits, produced via IdeS- and
GingisKHAN-based digestion. It was shown that MALDI-ISD
fragment ions were complementary to those observed in
electron-transfer dissociation experiments, and thus translated
in additional sequence coverage of the mAbs. It is noted that
the combination of top-down and middle-down experiments
increased total sequence coverage, however IdeS- and
GingisKHAN-based digestions are not needed to map the
antibody CDRs.
Postprocessing of transients (using AutoVectis) was used to
generate absorption-mode FT mass spectra with improved
resolving power resulting in unambiguous assignments of
further resolved fragment ions. It is noted that although
sequence coverage hardly increased, the superior quality of
aFT spectra led to a more conﬁdent characterization of both
N- and C-terminal parts of NIST mAb and trastuzumab
compared to mFT mass spectra of the same samples.
Finally, direct analysis of IdeS digests by MALDI FT-ICR
MS provided a snapshot of the most abundant Fc-glycans that
agreed with previously reported in-depth microheterogeneity
analysis of mAb Fc-glycosylation. We envision integration of
this strategy into a multimethod approach designed for the in-
depth structural characterization of complex proteins such as
mAbs.
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Figure 5. Microheterogeneity of Fc-glycosylation. MALDI FT-ICR MS spectra of IdeS-digested mAbs: (A) NIST mAb and (B) trastuzumab. For
NIST mAb at least seven diﬀerent N-glycans are observed at the Fc-part of Hc (detected as [M + 2H]2+ ions).
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Sanglier-Cianfeŕani, S. Anal. Chem. 2013, 85, 715−736.
(19) Bogdanov, B.; Smith, R. D. Mass Spectrom. Rev. 2005, 24, 168−
200.
(20) Srzentic, K.; Nagornov, K. O.; Fornelli, L.; Lobas, A. A.; Ayoub,
D.; Kozhinov, A.; Gasilova, N.; Menin, L.; Beck, A.; Gorshkov, M.;
Aizikov, K.; Tsybin, Y. O. Anal. Chem. 2018, 90, 12527−12535.
(21) Mao, Y.; Valeja, S. G.; Rouse, J. C.; Hendrickson, C. L.;
Marshall, A. G. Anal. Chem. 2013, 85, 4239−4246.
(22) Ait-Belkacem, R.; Berenguer, C.; Villard, C.; Ouafik, L. H.;
Figarella-Branger, D.; Beck, A.; Chinot, O.; Lafitte, D. mAbs 2014, 6,
1385−1393.
(23) Bakalarski, C. E.; Gan, Y.; Wertz, I.; Lill, J. R.; Sandoval, W.
Nat. Biotechnol. 2016, 34, 811−813.
(24) Fukuyama, Y.; Iwamoto, S.; Tanaka, K. J. Mass Spectrom. 2006,
41, 191−201.
(25) Quinton, L.; Demeure, K.; Dobson, R.; Gilles, N.; Gabelica, V.;
De Pauw, E. J. Proteome Res. 2007, 6, 3216−3223.
(26) Nicolardi, S.; Switzar, L.; Deelder, A. M.; Palmblad, M.; van der
Burgt, Y. E. Anal. Chem. 2015, 87, 3429−3437.
(27) Marshall, A. G.; Verdun, F. R. Fourier Transforms in NMR,
Optical, and Mass Spectrometry; Elsevier, 1990, ISBN 9781483293844.
(28) Xian, F.; Hendrickson, C. L.; Blakney, G. T.; Beu, S. C.;
Marshall, A. G. Anal. Chem. 2010, 82, 8807−8812.
(29) Qi, Y.; Thompson, C. J.; Van Orden, S. L.; O’Connor, P. B. J.
Am. Soc. Mass Spectrom. 2011, 22, 138−147.
(30) Lange, O.; Damoc, E.; Wieghaus, A.; Makarov, A. Int. J. Mass
Spectrom. 2014, 369, 16−22.
(31) Kilgour, D. P. A.; Wills, R.; Qi, Y.; O’Connor, P. B. Anal. Chem.
2013, 85, 3903−3911.
(32) Srzentic, K.; Fornelli, L.; Tsybin, Y.; Loo, J.; Agar, J.; Chamot-
Rooke, J.; Danis, P.; Ge, Y.; Goodlett, D.; Kelleher, N.; Pasa Tolic, L.;
Smith, L.; Toby, T.; Nagornov, K.; Brodbelt, J.; Greer, S.; Dupre,́ M.;
Clarke, D.; Lin, Z.; Haselmann, K., et al. 66th ASMS Conference on
Mass Spectrometry and Allied Topics 2018; San Diego, CA, 2018;
Poster ID 294106.
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